UBS O'Connor’s Akero Therapeutics AKRO Stock Holding History

UBS O'Connor’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,800	Closed	-$761K	–	375
2025 Q1	$761K	Buy	+18,800	New	+$797K	0.02%	205

Other funds holding AKRO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS O'Connor's AKRO Position: Q2 2025 in Review

UBS O'Connor sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 18,800 shares — an estimated $761K sold.

UBS O'Connor first reported a position in AKRO in Q1 2025 and held it in 1 quarter. The position peaked at $761K in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

UBS O'Connor reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
UBS O'Connor sold 18,800 Akero Therapeutics shares in Q2 2025, an estimated $761K.
UBS O'Connor first reported a position in Akero Therapeutics in Q1 2025 and held it in 1 quarter.
UBS O'Connor's Akero Therapeutics position peaked at $761K in Q1 2025.
257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.